Citadel Advisors
INBX icon

Citadel Advisors’s Inhibrx INBX Stock Holding History

Citadel Advisors’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.23M Buy
33,157
+6,257
+23% +$464K ﹤0.01% 5861
2025
Q4 		$2.13M Sell
26,900
-30,294
-53% -$2.06M ﹤0.01% 5792
2025
Q3 		$1.93M Buy
+57,194
New +$1.41M ﹤0.01% 6146

Other funds holding INBX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Citadel Advisors's INBX Position: Q1 2026 in Review

Citadel Advisors increased its Inhibrx (INBX) stake by 23% in Q1 2026, buying an estimated $464K and bringing the position to 33,157 shares worth $2.23M. The position accounts for ﹤0.01% of the portfolio, ranked #5861.

Citadel Advisors first reported a position in INBX in Q3 2025 and has held it in 3 quarters since. 135 funds tracked by Wall St. Rank hold INBX as of Q1 2026.

  • Citadel Advisors held 33,157 shares of Inhibrx worth $2.23M as of Q1 2026.
  • Citadel Advisors bought 6,257 Inhibrx shares in Q1 2026, an estimated $464K.
  • Inhibrx made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5861 holding.
  • Citadel Advisors first reported a position in Inhibrx in Q3 2025 and has held it in 3 quarters since.
  • 135 funds tracked by Wall St. Rank held Inhibrx as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.